Ascentage continues trend of large Chinese-led rounds

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised about $150 million in a series C round co-led by existing investors YuanMing Prudence Fund

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE